Dyne Therapeutics (DYN) Free Cash Flow (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Free Cash Flow of -$125.7 million for Q2 2026, down 32.63% year-over-year from -$186.6 million in Q2 2025, and up 13.41% quarter-over-quarter from -$145.1 million in Q1 2026.
Powered by 
Analysis
Dyne Therapeutics (DYN) Free Cash Flow (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Free Cash Flow for 8 consecutive years, with -$125.7 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Free Cash Flow fell 32.63% year-over-year to -$125.7 million; the TTM figure through Jun 2026 stood at -$491.2 million (down 35.71% YoY), while the FY2025 annual figure was -$422.0 million, down 43.17% from the prior year.
- Free Cash Flow climbed to -$125.7 million in Q2 2026 per DYN's latest filing, from -$145.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$29.7 million in Q4 2022 and bottomed at -$145.1 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$74.1 million across 5 years, with a median of -$65.4 million in 2023.
- On a YoY basis, Free Cash Flow climbed as much as 33.45% in 2022 and fell as far as 182.57% in 2022.
- Dyne Therapeutics' Free Cash Flow stood at -$29.7 million in 2022, then decreased by 18.1% to -$35.1 million in 2023, then tumbled by 143.42% to -$85.4 million in 2024, then slumped by 30.94% to -$111.8 million in 2025, then dropped by 12.39% to -$125.7 million in 2026.
- Business Quant data shows DYN's Free Cash Flow at -$125.7 million in Q2 2026, -$145.1 million in Q1 2026, and -$111.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Dyne Therapeutics | 4.02 Bn | 4.02 Bn | - | -125.69 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -125.69 Mn |
| Mar 31, 2026 | -145.14 Mn |
| Dec 31, 2025 | -111.83 Mn |
| Sep 30, 2025 | -108.53 Mn |
| Jun 30, 2025 | -94.76 Mn |
| Mar 31, 2025 | -106.87 Mn |
| Dec 31, 2024 | -85.41 Mn |
| Sep 30, 2024 | -74.88 Mn |
| Jun 30, 2024 | -55.73 Mn |
| Mar 31, 2024 | -78.73 Mn |
| Dec 31, 2023 | -35.09 Mn |
| Sep 30, 2023 | -50.77 Mn |
| Jun 30, 2023 | -55.89 Mn |
| Mar 31, 2023 | -47.14 Mn |
| Dec 31, 2022 | -29.71 Mn |
| Sep 30, 2022 | -43.69 Mn |
| Jun 30, 2022 | -31.17 Mn |
| Mar 31, 2022 | -52.14 Mn |
| Dec 31, 2021 | -30.06 Mn |
| Sep 30, 2021 | -27.83 Mn |